Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?

Imagem de Miniatura
Arquivos
art_AIKAWA_Intestinal_microsporidiosis_a_hidden_risk_in_rheumatic_disease_2011.PDF (91.4 KB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
SAAD, Carla Goncalves Schain
TOLEDO, Roberto Acayaba de
Citação
CLINICS, v.66, n.7, p.1171-1175, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: Immunosuppressed patients are at risk of microsporidiosis, and this parasitosis has an increased rate of dissemination in this population. Our objective was to evaluate the presence of microsporidiosis and other intestinal parasites in rheumatic disease patients undergoing anti-tumor necrosis factor/disease-modifying anti-rheumatic drug treatment. METHODS: Ninety-eight patients (47 with rheumatoid arthritis, 31 with ankylosing spondylitis and 11 with psoriatic arthritis) and 92 healthy control patients were enrolled in the study. Three stool samples and cultures were collected from each subject. RESULTS: The frequency of microsporidia was significantly higher in rheumatic disease patients than in control subjects (36 vs. 4%, respectively; p<0.0001), as well as in those with rheumatic diseases (32 vs. 4%, respectively; p<0.0001), ankylosing spondylitis (45 vs. 4%, respectively; p<0.0001) and psoriatic arthritis (40 vs. 4%, respectively; p<0.0001), despite a similar social-economic class distribution in both the patient and control groups (p = 0.1153). Of note, concomitant fecal leukocytes were observed in the majority of the microsporidia-positive patients (79.5%). Approximately 80% of the patients had gastrointestinal symptoms, such as diarrhea (26%), abdominal pain (31%) and weight loss (5%), although the frequencies of these symptoms were comparable in patients with and without this infection (p>0.05). Rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis disease activity parameters were comparable in both groups (p>0.05). The duration of anti-tumor necrosis factor/disease-modifying anti-rheumatic drugs and glucocorticoid use were also similar in both groups. CONCLUSION: We have documented that microsporidiosis with intestinal mucosa disruption is frequent in patients undergoing concomitant anti-tumor necrosis factor/disease-modifying anti-rheumatic drug therapy. Impaired host defenses due to the combination of the underlying disease and the immunosuppressive therapy is the most likely explanation for this finding, and this increased susceptibility reinforces the need for the investigation of microsporidia and implementation of treatment strategies in this population.
Palavras-chave
Microsporidia, Parasitosis, Anti-TNF, Rheumatoid arthritis, Ankylosing spondylitis
URI
https://observatorio.fm.usp.br/handle/OPI/22565
Referências
  1. Almeida PM, 1991, CRITERIO CLASSE EC A, P1
  2. Punzi L, 2007, AUTOIMMUN REV, V6, P524, DOI 10.1016/j.autrev.2006.12.003
  3. Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
  4. Schiff MH, 2006, ANN RHEUM DIS, V65, P889, DOI 10.1136/ard.2005.043166
  5. Franzen C, 1999, DIAGN MICR INFEC DIS, V34, P245, DOI 10.1016/S0732-8893(99)00003-6
  6. Elenkov IJ, 2004, ANN NY ACAD SCI, V1024, P138, DOI 10.1196/annals.1321.010
  7. Farthing MJG, 2006, NAT CLIN PRACT GASTR, V3, P436, DOI 10.1038/ncpgasthep0557
  8. Oyarzabal OA, 2005, APPL ENVIRON MICROB, V71, P3351, DOI 10.1128/AEM.71.6.3351-2254.2005
  9. Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217
  10. Burmester GR, 2009, ANN RHEUM DIS, V68, P1863, DOI 10.1136/ard.2008.102103
  11. Chacin-Bonilla L, 2006, AM J TROP MED HYG, V74, P482
  12. Didier ES, 2005, ACTA TROP, V94, P61, DOI 10.1016/j.actaatropica.2005.01.010
  13. Rychly DJ, 2005, PHARMACOTHERAPY, V25, P1181, DOI 10.1592/phco.2005.25.9.1181
  14. Stark D, 2009, CLIN MICROBIOL REV, V22, P634, DOI 10.1128/CMR.00017-09
  15. Furst DE, 2010, SEMIN ARTHRITIS RHEU, V39, P327, DOI 10.1016/j.semarthrit.2008.10.002
  16. GARRETT S, 1994, J RHEUMATOL, V21, P2286
  17. Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103
  18. Didier ES, 2006, CURR OPIN INFECT DIS, V19, P485, DOI 10.1097/01.qco.0000244055.46382.23
  19. RYAN NJ, 1993, J CLIN MICROBIOL, V31, P3264
  20. Bernatsky S, 2007, RHEUMATOLOGY, V46, P1157, DOI 10.1093/rheumatology/kem076
  21. ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
  22. Bennett P, 1968, POPULATION STUDIES R, P456
  23. Boatright MD, 2005, ARTHRITIS RHEUM, V52, P1336, DOI 10.1002/art.20882
  24. DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003
  25. Galván Ana Luz, 2006, Biomedica, V26, P126
  26. Gupta D. N., 1997, Journal of Communicable Diseases, V29, P329
  27. Haroon N, 2009, CURR OPIN RHEUMATOL, V21, P397, DOI 10.1097/BOR.0b013e32832c792d
  28. HENRIKSEN SA, 1981, ACTA VET SCAND, V22, P594
  29. JINDAL N, 1991, Indian Journal of Medical Sciences, V45, P261
  30. Khan IA, 2004, WORLD CL PARASITES, V9, P135
  31. KOGA K, 1990, J TROP MED HYG, V93, P183
  32. Krishnamurthy R, 2007, JCR-J CLIN RHEUMATOL, V13, P150, DOI 10.1097/RHU.0b013e3180690933
  33. MARANGI A, 1995, MICROBIOLOGICA, V18, P435
  34. PEREIRA DB, 1979, REV BRAS PESQUI MED, V12, P351
  35. PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
  36. PRICE DL, 1981, J CLIN MICROBIOL, V14, P656

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/36
Artigos e Materiais de Revistas Científicas - LIM/48